Falling Fed rates and favorable policies make XLV a strong healthcare ETF pick. Read here for an analysis of its growth ...

Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of ...

Trump, in an effort to lower drug costs for U.S. patients who pay far more than in other wealthy nations, has so far struck ...

Biotech stocks rebound after years of weakness as M&A, lower rates and easing policy fears draw investors back to the sector.

The moves, to lower the cost of a drug prescribed to women going through IVF and boost employer coverage, follow Trump’s ...

Enfortumab vedotin plus pembrolizumab improved EFS, OS, and pCR rates in MIBC patients ineligible for cisplatin-based chemotherapy. The combination therapy showed a median EFS and OS that were not ...

Dato-DXd showed a 43% reduction in disease progression risk and a 21% reduction in death risk compared to chemotherapy in TNBC patients ineligible for immunotherapy. The TROPION-Breast02 trial ...

Findings point to importance of RSV vaccination in older patients with systemic autoimmune rheumatic diseases.

OPKO Health, Inc. is refocusing on drug development, selling BioReference Lab assets to strengthen its balance sheet. Learn ...

The Trump administration has struck a deal with EMD Serono to lower drug prices — part of a larger push from the ...

Although experts may disagree on how to classify neurogenic rosacea pain, they advise dermatologists to get more comfortable ...